U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Google Secures Pentagon AI Deal for Classified Projects 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
IRVINE, Calif., Feb. 18, 2016 -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2015 financial results, which will take place on Monday, February 22, 2016 after the close of the market.
Endologix will hold a conference call on Monday, February 22, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.
After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through February 22, 2017. In addition, a transcript will be posted to the website and a telephonic replay of the call will be available until February 29, 2016. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13629814.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
ENDOLOGIX CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
